RLAY Quote, Financials, Valuation and Earnings

Immunome, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of -1080.87%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Immunome, Inc.'s return on equity of -90.08%.

Relay Therapeutics, Inc. has a consensus price target of $14.55, signalling upside risk potential of 90.14%. On the other hand Immunome, Inc. has an analysts' consensus of $34.50 which suggests that it could grow by 39.39%. Given that Relay Therapeutics, Inc. has higher upside potential than Immunome, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Immunome, Inc..

Relay Therapeutics, Inc. has a beta of 1.548, which suggesting that the stock is 54.758% more volatile than S&P 500. In comparison Immunome, Inc. has a beta of 2.220, suggesting its more volatile than the S&P 500 by 122.014%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunome, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Immunome, Inc. pays out -- of its earnings as a dividend.

Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Immunome, Inc. quarterly revenues of --. Relay Therapeutics, Inc.'s net income of -$74.1M is lower than Immunome, Inc.'s net income of -$57.5M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Immunome, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 155.69x versus 202.70x for Immunome, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of 31.72%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Eli Lilly & Co.'s return on equity of 106.26%.

Relay Therapeutics, Inc. has a consensus price target of $14.55, signalling upside risk potential of 90.14%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,133.93 which suggests that it could grow by 10.76%. Given that Relay Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Relay Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Relay Therapeutics, Inc. has a beta of 1.548, which suggesting that the stock is 54.758% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Relay Therapeutics, Inc.'s net income of -$74.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 155.69x versus 15.71x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Prelude Therapeutics, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of -303.46%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Prelude Therapeutics, Inc.'s return on equity of -106.36%.

Relay Therapeutics, Inc. has a consensus price target of $14.55, signalling upside risk potential of 90.14%. On the other hand Prelude Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 103.05%. Given that Prelude Therapeutics, Inc. has higher upside potential than Relay Therapeutics, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Relay Therapeutics, Inc..

Relay Therapeutics, Inc. has a beta of 1.548, which suggesting that the stock is 54.758% more volatile than S&P 500. In comparison Prelude Therapeutics, Inc. has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.343%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prelude Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Prelude Therapeutics, Inc. pays out -- of its earnings as a dividend.

Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Prelude Therapeutics, Inc. quarterly revenues of $6.5M. Relay Therapeutics, Inc.'s net income of -$74.1M is lower than Prelude Therapeutics, Inc.'s net income of -$19.7M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Prelude Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 155.69x versus 13.29x for Prelude Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of 18.08%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.

Relay Therapeutics, Inc. has a consensus price target of $14.55, signalling upside risk potential of 90.14%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 40.38%. Given that Relay Therapeutics, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Theravance Biopharma, Inc..

Relay Therapeutics, Inc. has a beta of 1.548, which suggesting that the stock is 54.758% more volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.139, suggesting its less volatile than the S&P 500 by 86.12%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.

Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Theravance Biopharma, Inc. quarterly revenues of $20M. Relay Therapeutics, Inc.'s net income of -$74.1M is lower than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 33.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 155.69x versus 11.94x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.